Cytokine storms caused by novel coronavirus 2019 and treatment for cardiac injury

Area of Science:

• Infectious Diseases
• Immunology
• Pharmacology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has spread globally since December 2019.
• Cytokine storm syndrome (CSS) is increasingly recognized as a key factor in the progression of COVID-19 pneumonia to critical illness and mortality.
• Current COVID-19 treatment strategies are focusing on the early identification and management of CSS.

Purpose of the Study:

• To review the pathophysiology of cytokine storms.
• To explore potential pharmacotherapies for managing cytokine storms.
• To provide a reference for clinical treatment of CSS in COVID-19 patients.

Main Methods:

• Literature review of cytokine storms.
• Exploratory review of pharmacotherapeutic agents for CSS.
• Analysis of current treatment approaches for COVID-19 associated CSS.

Main Results:

• Cytokine storms are implicated in the severe manifestations of COVID-19.
• No specific drug is currently approved for CSS treatment.
• Pharmacotherapy review highlights potential treatment avenues.

Conclusions:

• Early identification and intervention for CSS are vital for improving COVID-19 patient outcomes.
• Further research into targeted pharmacotherapy for CSS is warranted.
• This review offers insights into managing CSS for clinicians treating COVID-19.